Compare PDX & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDX | NVAX |
|---|---|---|
| Founded | 2019 | 1987 |
| Country | NY | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 996.5M | 1.1B |
| IPO Year | N/A | 1995 |
| Metric | PDX | NVAX |
|---|---|---|
| Price | $21.69 | $6.87 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $10.78 |
| AVG Volume (30 Days) | N/A | ★ 3.9M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 4.95% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.07 |
| Revenue | N/A | ★ $1,064,651,000.00 |
| Revenue This Year | N/A | $58.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.34 |
| Revenue Growth | N/A | ★ 20.27 |
| 52 Week Low | $13.52 | $5.01 |
| 52 Week High | $21.05 | $11.55 |
| Indicator | PDX | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 44.78 | 44.01 |
| Support Level | $21.19 | $6.56 |
| Resistance Level | $22.16 | $7.03 |
| Average True Range (ATR) | 0.42 | 0.25 |
| MACD | 0.07 | 0.08 |
| Stochastic Oscillator | 50.96 | 81.33 |
PIMCO Dynamic Income Strategy Fund is a non-diversified, limited-term, closed-end management investment company. It seeks current income as a primary objective and capital appreciation as a secondary objective. The fund makes investments using a dynamic asset allocation plan among multiple sectors in the public and private credit markets globally, including corporate debt, mortgage-related and other asset-backed instruments, government and sovereign debt, taxable municipal bonds, and other fixed, variable, and floating-rate income-producing securities of U.S. and foreign issuers, including emerging market issuers and real estate-related investments.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.